ALNY Alnylam Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 12 January 2020 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

   − Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Preliminary Global Net Product Revenues of Approximately $56 Million and $166 Million, Respectively – – As of Year-End 2019, Over 750 Patients

2. 10 January 2020 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

   − Company Plans to Complete Submission in Early 2020 – – Lumasiran Granted Pediatric Rare Disease Designation by FDA for the Treatment of PH1 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi

3. 06 January 2020 Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference

   Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January

4. 17 December 2019 Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

   − Lumasiran Met Primary and All Tested Secondary Endpoints, with Significant Reduction in Urinary Oxalate Levels Relative to Placebo – − Alnylam Intends to File New Drug Application (NDA) and Marketing Authorisation

5. 26 November 2019 Alnylam to Webcast Presentations at Upcoming December Investor Conferences

   Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2nd Annual HealthCONx

6. 22 November 2019 Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day

   − Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late-Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates

7. 20 November 2019 Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)

   − Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial

8. 20 November 2019 Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

   − GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA

9. 19 November 2019 Alnylam Announces Second Annual Advocacy for Impact Grants Program

   − Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities − − Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary

10. 12 November 2019 Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019

11. 09 November 2019 Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

    − Initial Results From ILLUMINATE-C Expected in Late 2020 – − In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline – Alnylam

12. 31 October 2019 Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity

    − Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide – − Initiated APOLLO-B Phase 3 Study of

13. 24 October 2019 Alnylam Named #1 Biopharma Employer by Science Magazine

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that Science magazine has named the company the world's number one employer in its annual survey of the biotech and

14. 15 October 2019 Alnylam's Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded

15. 10 October 2019 Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

    – Filing Marks the First RNAi Therapeutic to be Submitted for Potential Approval in Latin America – – Submission Made Under the Accelerated Regulatory Pathway for Rare Diseases – Alnylam Pharmaceuticals, Inc.

16. 26 September 2019 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

17. 16 September 2019 Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

    – APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated

18. 13 September 2019 Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on

19. 11 September 2019 1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day

    − Alnylam Supports Nearly 40 Organizations in Greater Boston, Philadelphia, Europe and Brazil in "Helping Hands" Community Service Day – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics

20. 10 September 2019 Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias

    − Porphyria Attack Reductions Observed in ENVISION Phase 3 Study Maintained with Ongoing Givosiran Dosing in Open-Label Extension (OLE) Study – − In ENVISION Phase 3 Study, Patients Receiving Givosiran Reported

21. 06 September 2019 Alnylam to Host Sixth Annual "RNAi Roundtable" Webcast Series

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to kick off its 6th annual series of "RNAi Roundtable" webcasts over the coming weeks. The series will

22. 05 September 2019 Yumanity Therapeutics Appoints Patricia Allen to its Board of Directors

    Ms. Allen Brings Over 25 Years of Financial Leadership Experience to the Company Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases,

23. 03 September 2019 Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients

    − Neurofilament Light Chain (NfL) Identified as a Potential Biomarker of Nerve Damage and Polyneuropathy due to hATTR Amyloidosis; ONPATTRO® (patisiran) Treatment Found to Reduce NfL Levels Relative to Placebo in APOLLO

24. 02 September 2019 Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in

25. 30 August 2019 Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Morgan Stanley Global Healthcare Conference on